Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 4, 2007, Pages 1767-1772

  Zuluaga, Maria Fernanda ^a   Mailhos, Carolina ^b   Robinson, Gregory ^b   Shima, David T ^b   Gurny, Robert ^a   Lange, Norbert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Eyetech Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOSENSITIZING AGENT; TETRAKIS(4 HYDROXYPHENYL)PORPHYRIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1 ANTAGONIST; VERTEPORFIN; BENZOPORPHYRIN DERIVATIVE; LIPOSOME; MESO TETRA (4 HYDROXYPHENYL)PORPHYRIN; MESO-TETRA-(4-HYDROXYPHENYL)PORPHYRIN; NANOPARTICLE; PORPHYRIN; RECOMBINANT PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL OCCLUSION; CHORIOALLANTOIS; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG POTENTIATION; EGG; EMBRYO; EMBRYO DEVELOPMENT; EPIFLUORESCENCE MICROSCOPE; FLUORESCENCE ANGIOGRAPHY; INCUBATION TIME; MONOTHERAPY; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVASCULARIZATION; ANGIOGENESIS; ANIMAL; CHICK EMBRYO; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENCE MICROSCOPY; HUMAN; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; VASCULARIZATION;

ANIMALS; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FLUORESCEIN ANGIOGRAPHY; HUMANS; LIPOSOMES; MACULAR DEGENERATION; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; NEOVASCULARIZATION, PHYSIOLOGIC; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 34248370178     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-1224     Document Type: Article

References (35)

1. Kulkarni AD, Kuppermann BD. Wet age-related macular degeneration. Adv Drug Deliv Rev. 2005;57:1994-2009.
2. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195-214.
3. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group: acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials - TAP and VIP report no. 3. Am J Ophthalmol. 2004;137:683-696.
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541-560.
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136:407-418.
6. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol. 2003;136:1049-1061.
7. Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G, Michels SM. Effects of verteporfin therapy on central visual field function. Ophthalmology. 2004;111:931-939.
8. Lopez PF, Sippy BD, Lambert HM, Tach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
9. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
10. FranK RN, Amin RH. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122:393-403.
11. Hera R, Keramidas M, Peoc'h M, Mouillon M, Romanet JP, Feige JJ. Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol. 2005;139:589-596.
12. Ng EWM, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352-368.
13. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003;110:1517-1525.
14. Vargas A, Pegaz B, Debefve E, et al. Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. Int J Pharm. 2004;286:131-145.
15. Lange N, Ballini JP, Wagnieres G, van den Bergh H. A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. Invest Ophthalmol Vis Sci. 2001;42:38-46.
16. Osiecka B, Ziolkowski P, Gamiara E, Lis-Nawara A, White SG, Bonnett R. Determination of vascular-endothelial growth factor levels in serum from tumor-bearing BALB/c mice treated with photodynamic therapy. Med Sci Monit. 2003;9:110-114.
17. Zhang X, Jiang F, Zhang ZG, et al. Low-dose photodynamic therapy increases endothelial cell proliferation and VEGF expression in nude mice brain. Lasers Med Sci. 2005;20:74-79.
18. Uehara M, Inokuchi T, Sano K, ZuoLin W. Expression of vascular endothelial growth factor in mouse tumours subjected to photodynamic therapy. Eur J Cancer. 2001;37:2111-2115.
19. Gelisken F, Lafaut B, Inhoffen W, Voelker M, Grisanti S, Bartz-Schmidt KU. Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol. 2004;88:207-211.
20. Rudolf M, Michels S, Schlötzer-Schrehardt U, Schmidt-Erfurth U. Expression of angiogenic factors by photodynamic therapy. Klin Monatsbl Augenheilkd. 2004;221:1026-1032.
21. Zhou Q, Olivo M, Lye K, et al. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol. 2005;56:569-577.
22. Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 1999;137:91-98.
23. Cecic I, Parkins CS, Korbelik M. Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors. Photochem Photobiol. 2001;74:712-720.
24. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol. 2004;88:344-347.
25. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301-304.
26. Ratcliffe PJ, O'Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol. 1998;201:1153-1162.
27. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA. 1993;90:4304-4308.
28. Forsythe JA, Jiang B-H, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604-4613.
29. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GOH. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2003;44:4473-4480.
30. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
31. Witmer AN, Vrensen GFJM, Van Noorden CJF, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1-29.
32. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90:10705-10709.
33. Joon-Hwa Lee, Canny MD, De Erkenez A, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA. 2005;102:18902-18907.
34. Flamme I, von Reutern M, Drexler HCA, Syed-Ali S, Risau W. Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation. Dev Biol. 1995;171:399-414.
35. Yamaguchi S, Iwata K, Shibuya M. Soluble Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Commun. 2002;291:554-559.